Explore Latest News

Colorectal

Positive Phase III Data For Refractory Colorectal Cancer, But Where Does Zanzalintinib + Atezolizumab Fit?

Dr. Rodrigo C. Leão Edelmuth,

Hospital Israelita Albert Einstein

Genitourinary Cancers (GU)

Memorial Sloan Kettering's Dr. David Aggen On TAR-200 In BCG-Unresponsive NMIBC: A New Option & New Questions

Dr. Rodrigo C. Leão Edelmuth,

Hospital Israelita Albert Einstein

Breast Cancer

A New Option For ESR1-Mutated Breast Cancer: FDA Approves Vepdegestrant After Promising PFS Data

Kavontae Smalls

prostate

As precision medicine reshapes treatment strategies across oncology, PTEN deficiency is emerging as one of the most actionable and clinically urgent biomarkers in prostate cancer.

Dr. Rodrigo C. Leão Edelmuth,

Hospital Israelita Albert Einstein

Lung Cancer

What to Watch at ASCO 2026: Major Breakthroughs Poised to Reshape Cancer Care

Jayson Haedrich,

–

Hematologic Malignancies

Dr. Sameh Gaballa On Treating Relapsed Follicular Lymphoma: More Options, But No Clear Data On Sequencing

Dr. Natalie Rafaeli

Genitourinary Cancers (GU)

'We May Be Missing the Window': Rethinking When To Target The PI3K Pathway In Prostate Cancer

Dr. Rodrigo C. Leão Edelmuth,

Hospital Israelita Albert Einstein

Gastrointestinal Cancers (GI)

From ‘Undruggable’ To Actionable: RAS Inhibitors & A Potential New Era Of Targeted Therapy For Pancreatic Cancer

Dr. Kaique Filardi

Hematologic Malignancies

Roswell Park's Dr. Ehsan Malek On Sequencing Tec‑Dara & CAR T-Cell Therapy in RRMM

Dr. Kaique Filardi